Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
about
Clinical outcomes of biodegradable polymer drug-eluting stents for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trialsEfficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysisThe resolute™ integrity zotarolimus-eluting stent in coronary artery disease: a review.Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomizeA prospective, multi-centric, observational registry to evaluate performance of Excel™ DES in 'real world, all comers' patient population.Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis.Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up.Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis.Coronary stent thrombosis: current insights into new drug-eluting stent designsSeven-year clinical outcomes of sirolimus-eluting stent versus bare-metal stent: a matched analysis from a real world, single center registry.Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India.Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery.Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview.Drug- and Gene-eluting Stents for Preventing Coronary Restenosis.Current status of drug-eluting stents.Pharmacological prevention and management of restenosis.Local drug delivery for treatment of coronary and peripheral artery disease.Current status of the Xience V® everolimus-eluting coronary stent system.Recent developments in drug-eluting stents.Advantages and disadvantages of biodegradable platforms in drug eluting stents.Restenosis after PCI. Part 2: prevention and therapy.New technologies aimed at percutaneous intervention in the small coronary artery.Coronary stent choice in patients with acute myocardial infarction.Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.Dexamethasone-eluting vascular stents.Coronary stents: historical development, current status and future directions.Newly available and recent advances in drug-eluting stents.Second generation drug-eluting stents: a review of the everolimus-eluting platform.Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.Drug-eluting stents: the past, present, and future.Four-year clinical follow-up of the first-in-man randomized comparison of a novel sirolimus eluting stent with abluminal biodegradable polymer and ultra-thin strut cobalt-chromium alloy: the INSPIRON-I trial.Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.Bioresorbable Polymers and Stent Devices.Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents.A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
P2860
Q26859403-9655A8E4-130F-43CD-B4B2-F713E638A6BBQ28534994-A47235EE-BE3A-4B81-A312-61215C97635EQ33936124-4A78B151-5DEE-48D1-8DD5-3EAA666A7860Q34002205-837975FC-B560-47EB-8DF9-404A63813CBEQ34207990-66FC4851-6274-4C74-A5C4-0FE31B9198AFQ35028661-05AC0394-AC06-4EE5-9658-8C292378ED74Q35495452-FC167D16-40A2-482D-BC28-09D8C26AEC32Q35579187-008C4007-072F-4100-B330-298D1C335F17Q35843028-2C10392C-CD66-4C8F-A2BF-11D8A10FB239Q36514842-C7E88948-300E-457C-84CB-89FAD97B1BC1Q36675548-E62E5504-9297-4A4C-9BC4-799B07E4FCCAQ36705836-2D364B36-46C1-491B-BC18-621D9E49CACAQ37387136-8EBF3184-4425-4852-8CDF-8914B56E90BBQ37388164-4F37E299-4931-43AB-93AE-E69AED947825Q37464405-3A36CDA0-907A-44AB-ABBB-A9F0774F47CAQ37511128-18AC7048-1664-4DFD-8927-1120E8B96E54Q37526533-6F85DE2C-1084-4EA5-9804-63D96958500AQ37633078-56B9D5A2-2D9D-43F9-8EBD-CBE11ACF8EFDQ37725108-346A3B28-6843-47D2-934D-7E16AA927F05Q37756979-6A1D4C15-B349-4BC6-A36D-E405AAA344E3Q37765610-533C5A98-FDBC-4A5A-83A7-F2A46C1ED3D4Q37799356-C6C29D13-81B9-4598-B10E-0FB69018680FQ37833534-323F7F2A-B300-43ED-B385-DF6DAE6F87FCQ37866105-8079EB2A-D82C-45AD-BC72-1B683B573F25Q37944416-7E601A68-1322-4B3C-AE2F-75E32B0F377AQ37998111-54DD7246-E536-4371-A8B8-971B371F5F54Q38009703-B6F3E7E3-EDFA-4D78-827B-F3D18B458F25Q38059840-2B63077C-2F61-4E4C-B574-DD4F3A7B5E3FQ38078557-E8C3E59D-CB57-4B47-B90E-F39EA7A3DF79Q38093501-DB97E5CC-BFF5-4765-8149-D710A2613AE5Q38101962-ACF2E230-34C1-4366-9BCD-29FEC13C5FC1Q38127415-EC3FE0CA-DBC4-4A79-8A97-DDB21BFAB57CQ38183346-9AB4A020-D534-4EEE-AD8E-F3E4525262B8Q38344198-FEE8B8D4-1138-42C4-9FDA-77B49C009C7FQ38404744-6E3D78E1-C2D1-4F0A-AA88-AD42CD0F00ABQ38436521-A75B3B66-5D48-4100-83ED-51B27ED626E1Q38702003-3CB459AE-1874-4583-94A0-16F361AF0F8AQ38919254-B99B7570-556E-495B-B421-D46C1A804A8EQ39053571-0B2DC156-6853-4E4E-80EF-1F18D9CE7217Q40105594-81F6FADF-C22E-4C45-9A6B-0142DC1477C9
P2860
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Randomized, non-inferiority tr ...... ng Stents (ISAR-TEST-4) Trial.
@en
type
label
Randomized, non-inferiority tr ...... ng Stents (ISAR-TEST-4) Trial.
@en
prefLabel
Randomized, non-inferiority tr ...... ng Stents (ISAR-TEST-4) Trial.
@en
P2093
P2860
P50
P356
P1476
Randomized, non-inferiority tr ...... ng Stents (ISAR-TEST-4) Trial.
@en
P2093
Intracoronary Stenting and Ang ...... ts (ISAR-TEST-4) Investigators
Jürgen Pache
K Anette Birkmeier
Massimiliano Fusaro
Melchior Seyfarth
Steffen Massberg
P2860
P304
P356
10.1093/EURHEARTJ/EHP352
P50
P577
2009-08-30T00:00:00Z